Lux Biosciences Reports Phase 1 Safety Results - Clinically Meaningful Improvements

[RDAC]

Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for DRY EYE

http://www.businesswire.com/portal/s...66&newsLang=en